| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Cytos Biotechnology AG, Schlieren-Zürich, Switzerland; and
Paul Scherrer Institut, Villigen, Switzerland
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
is a simple and attractive method to reduce these two problems. CpGs packaged into VLPs are resistant to DNase I digestion, enhancing their stability. In addition, and in contrast to free CpGs, packaging CpGs prevents splenomegaly in mice, without affecting their immunostimulatory capacity. In fact, vaccination with CpG-loaded VLPs was able to induce high frequencies of peptide-specific CD8+ T cells (4–14%), protected from infection with recombinant vaccinia viruses, and eradicated established solid fibrosarcoma tumors. Thus, packaging CpGs into VLPs improves both their immunogenicity and pharmacodynamics. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
B into the nucleus (18, 19), inducing maturation of DCs.
CpGs are preferentially present in prokaryotic DNA and are rare in mammalian DNA (20, 21). Thus, CpGs are an invariant pattern associated with pathogens and are recognized as such by the innate immune system. However, due to the intensive cellular activation provoked by CpGs, considerable systemic side effects may occur, in particular splenomegaly or even lethal toxic shock (22, 23). The second problem of CpGs is their unfavorable pharmacokinetics, because they exhibit a short life span in vivo. In fact, CpG oligodeoxynucleotides (ODN) containing normal phosphodiesterbonds usually fail to enhance immune responses, unless givenrepeatedly (24). Therefore, CpGs are chemically modified by introducing phosphorothioate bonds to reduce this limitation. The drawbacks of these modified oligonucleotides are the very long tissue t1/2 of 
2 days (25) and the increased nonspecific binding to various proteins and cell types (26).
To deliver CpGs in a more specific fashion to professional APCs, to reduce their potentially serious side effects, and to enhance their stability, we packaged the synthetic DNA oligonucleotides into virus-like particles (VLPs). The hepatitis B core Ag (HBcAg) and the bacteriophage Q capsids were used in this study as model VLPs for the packaging of CpGs. These proteins are recombinantly produced in bacteria and can efficiently self-assemble into structured VLPs. The CTL epitope p33 derived from the lymphocytic choriomeningitis virus glycoprotein (LCMV-GP) was associated to the VLPs through two different approaches: it was genetically fused to the C terminus of the HBcAg monomers (27), whereas for the Q VLP the p33 peptide was chemically coupled via a bifunctional linker to lysins present in the Q protein structure (28). In both cases, the CpG ODNs were packaged inside the VLPs through binding to capsid-internal arginine repeats. Such VLPs packaged with various CpG sequences (with phosphorothioate and also with normal phosphodiester bonds) exhibited enhanced adjuvant properties in the absence of significant side effects and induced strong immune responses in mice. When compared side by side, VLPs containing CpGs induced stronger CTL responses than recombinant vaccinia viruses or CpGs delivered together with peptide in liposomes. The induced responses protected mice from viral infections and eradicated established solid fibrosarcoma tumors.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Production, purification, and characterization of recombinant hepatitis B core p33-VLPs and Q VLPs were previously described in detail (27, 29, 30).
Chemical coupling of p33 to Q VLP
Purified Q VLPs (1.5 mg/ml in 20 mM HEPES, 150 mM NaCl, pH 7.2) were derivatized by a 30-min incubation at room temperature with a 10-fold molar excess of succinimidyl-6-(-maleimidopropionamido)hexanoate (Pierce, Rockford, IL). Free cross-linker was removed by extensive dialysis against 20 mM HEPES, pH 7.2. Peptide p33 was produced in a modified version with additional 3 aa (GGC) added to the C terminus (p33-GGC) (EMC Microcollections GmbH, Tübingen, Germany) to allow coupling to VLPs. Derivatized Q VLPs and p33-GGC (peptide at 5-fold molar excess) were then incubated for 2 h at room temperature to allow cross-linking. Free p33-GGC was removed by dialysis against 20 mM HEPES, pH 7.2, using DispoDialyser membranes with a molecular mass cutoff of 300 kDa (Spectrum Medical Industries, Rancho Dominguez, CA). Efficiency of cross-linking was analyzed by SDS-PAGE.
CpG ODN sequences
CpGs with normal phosphodiester backbone or with DNase-protected phosphorothioate bonds were synthesized by Microsynth AG (Balgach, Switzerland). The following CpG oligonucleotide sequences were used: 1668, 5'-TCCATGACGTTCCTGAATAAT-3'; 1585, 5'-GGGGTCAACGTTGAGGGGGG-3'; 1826, 5'-TCCATGACGTTCCTGACGTT-3'; G3, 5'-GGGGACGATCGTCGGGGGG-3'; G6, 5'-GGGGGGCGACGACGATCGTCGTCGGGGGGG-3'; Liang2, 5'-GAGACCCTGAACAGTTGATC-3'.
Packaging of CpGs into p33-VLPs
Packaging of CpGs into HBcAg and Q VLPs was performed with the same protocol, with the sole exception that HBcAg VLPs were dissolved in PBS, whereas Q particles were solubilized in 20 mM HEPES. Briefly, bacterial RNA present in p33-VLPs was eliminated by incubating the capsid preparations (0.5 mg/ml concentration) with RNase A (0.2 mg/ml concentration) for at least 2 h at 37°C. Packaging of CpG oligonucleotides into the p33-VLPs was achieved by adding CpGs to RNase-treated p33-VLPs to a final concentration of 120 nmol/ml for another 3 h. The p33-VLPs loaded with CpGs were treated with DNase I (200 U/ml) for 5 h at 37°C to test the enhanced stability of packaged CpG. p33-VLPs loaded with CpGs used for immunization of mice were first extensively dialyzed with a 300-kDa molecular weight cut-off membrane (Spectrum Medical Industries) to eliminate unbound oligonucleotides from p33-VLPs. Analysis of CpG packaging into p33-VLPs was done by loading 15 µg of protein on 1% agarose gels and run for 30 min at 100 V. The presence of nucleic acids was assessed by ethidium bromide staining, while VLPs were detected through Coomassie blue staining of the gels. The Gene Ruler, 1-kb DNA Ladder (MBI Fermentas GmbH, St. Leon-Rot, Germany), was used as reference.
Preparation of liposomes
Liposomes were produced, as previously described (31). Briefly, small unilamellar liposomes were generated by freeze thawing, followed by sequential filter extrusion. The liposomal composition was 200 mg/ml soy phosphatidylcholine, 25 mg/ml cholesterol, and 1.2 mg/ml DL-
-tocopherol. The dried lipid mixture was solubilized with 1 mg/ml or 50 µg/ml p33 peptide (KAVYNFATM) alone or with 100 nmol/ml CpGs (ODN1668pt), subjected to three to five freeze-thaw cycles, and repeatedly extruded through Nucleopore filters of 0.8-, 0.4-, and 0.2-µm pore size (Sterico AG, Dietikon, Switzerland). Unencapsulated peptide and CpGs were removed by dialysis. Liposome size was determined by laser light scattering (Submicron Particle Sizer Model 370; Nicomp, Santa Barbara, CA)
Assessment of antiviral immunity
To examine antiviral immunity, vaccinated C57BL/6 mice were infected i.v. 12 days after priming with 200 PFU LCMV strain WE. Five days later, spleens were isolated and LCMV titers were determined by a LCMV focus-forming assay, as described (32). Alternatively, female C57BL/6 mice were infected i.p. with 1.5 x 106 PFU or 4 x 106 PFU recombinant vaccinia virus. Five days later, ovaries were collected and the vaccinia titers were determined on BSC 40 cells, as described (33).
Cytotoxicity assay
For detection of primary ex vivo cytotoxicity, effector cell suspensions were prepared from spleens of vaccinated mice 9 days after priming. EL-4 cells were pulsed with p33 peptide (10-6 M, 2 h at 37°C in 2% FCS MEM medium) and used in a 5-h 51Cr release assay (33). Unlabeled EL-4 cells were used as a control. Radioactivity in cell culture supernatants was measured in a Cobra II counter (Canberra Packard, Downers Grove, IL). Spontaneous release was always <10%.
Assessment of antitumor immunity
Solid tumors were obtained by s.c. implanting MC57G-GP tumor cells expressing the LCMV-GP in H-2b RAG-/- mice. Tumors were sized in 0.2 x 0.2 x 0.2-cm pieces and implanted into the flank of C57BL/6 mice. Tumor growth was monitored by measuring the orthogonal diameters weekly, and the tumor size was calculated by multiplication of the two diameters. Mice were vaccinated s.c. once the tumors had reached a size of >0.64 cm2. Mice in which tumors were reaching sizes of >3–4 cm2 were sacrificed for regulatory reasons.
Statistical analysis
Unless noted, data are presented as mean ± SD. Comparisons between two groups were performed by two-tailed Student’s t test. A p value <0.05 was considered as significant and indicated with * in the figures.
For the tumor experiments, the statistical significances were calculated by comparing the survival rates of treated vs untreated mice in two-tailed Student’s t tests.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
As model VLPs for packaging CpG-containing DNA oligonucleotides, we used the HBcAg and the bacteriophage Q capsids. The MHC class I-restricted p33 peptide derived from the glycoprotein of LCMV was genetically fused to HBcAg and, respectively, chemically coupled to Q via the succinimidyl-6-(-maleimidopropionamido)hexanoate bifunctional linker. For both VLP types and epitope attachment strategies, the VLPs maintained their assembly capacity (27, 34) (data not shown).
HBcAg p33-VLPs run as single bands in Coomassie blue-stained agarose gels (Fig. 1A). Staining of a parallel gel with ethidium bromide demonstrated that the particles carried nucleic acid (Fig. 1A). The nucleic acids were bound to the internal DNA/RNA binding site of the particles, because deletion mutants missing the relevant arginine-rich repeats present between aa 149–183 of the HBc protein (HBcAg VLPDEL) failed to package the nucleic acids (Fig. 1A). Note that HBcAg VLPDEL have a slower migration rate on agarose gels than full-length HBcAg VLPs, most probably because of the different electrical charge of the two macromolecular complexes (28). To test whether HBcAg carries RNA or DNA, native particles or proteinase K-digested particles (data not shown) were treated with RNase A or DNase I (Fig. 1A). RNase treatment almost completely removed the nucleic acid signal, while DNase had no measurable effect. Thus, recombinantly produced HBcAg carries primarily RNA bound to C-terminal arginine-rich repeats, confirming recent results obtained by Riedl et al. (35). Interestingly, only RNase treatment of full-length HBcAg VLPs, but not of VLPDEL, produced a protein smear on the agarose gels: a possible explanation for this phenomenon could be that RNase-treated HBcAg p33-VLPs, which, as confirmed by electron microscopy analysis, maintained their particulate structure after enzyme digestion (data not shown), may contain different residual RNA traces and therefore possess heterogeneous electrical charges.
|
2 nm diameter present in the capside structure (36, 37, 38) and replace RNA. Addition of either type of oligonucleotides largely preserved the protein and nucleic acid bands observed in agarose gels (Fig. 1B). Thus, HBcAg p33-VLPs were able to bind ODN1668po and ODN1668pt. In contrast, HBcAg lacking the RNA/DNA binding site did not package CpGs (Fig. 1B). To test whether ODN1668po packaged in HBcAg were protected from degradation, p33-VLPs loaded with CpG were treated with DNase I before analysis on agarose gels (Fig. 1C). Although free CpG were readily digested by DNase, packaged CpG were largely protected (Fig. 1C) (note that DNase enzymes are generally larger than RNases and may not be able to enter the VLP particles). To investigate the CpG concentration packaged into VLPs, HBcAg p33-VLPs packaged with ODN1668pt were digested with proteinase K, and the packaged CpG oligonucleotides were recovered by phenol extraction and subsequent DNA precipitation. The CpG content of HBcAg p33-VLPs was calculated by running the dissolved oligonucleotides on an agarose gel and comparing the intensity of the CpG band with a titration curve of known ODN1668pt concentrations. Fig. 1D shows that 80 µg of packaged HBcAg p33-VLPs contain 0.5 nmol of oligonucleotides: This means that every VLP is loaded on average with 30 ODN1668pt molecules. Note that for the packaging of oligonucleotides with different CpG sequences but of the same length, similar results were obtained (data not shown).
CpGs were packaged into Q particles (dissolved in 20 mM HEPES) with the same protocol as used for HBcAg VLPs. Efficiency of Q packaging was analyzed in the same way as described in Fig. 1, and comparable results were obtained (data not shown). Specifically, Q packaged with the ODNG3po CpGs contained 85 DNA molecules per VLP capside on average, whereas Q packaged with the ODNG6po CpGs could be loaded with 25 DNA molecules per VLP particle (data not shown).
HBcAg p33-VLPs are processed in vivo for Ag presentation by DCs, but not by B or T cells
In previous studies, we have shown that DCs of lymphoid (CD11c+CD8+) and myeloid (CD11c+CD8-) origin and also macrophages (M
) (CD11b+) can take up HBcAg p33-VLPs for Ag processing and presentation to p33-specific T cells (27, 34). In vitro and in vivo assays indicated that DCs can cross-present the p33 epitope via a TAP-dependent endosome-to-cytosol pathway and via a TAP-independent pathway in which loading of MHC class I molecules presumably occurs within the endosome. In contrast, M seem to cross-present p33 exclusively via the second mechanism (direct endosomal loading).
To strengthen the hypothesis that only professional APCs are able to load p33 on MHC class I molecules, groups of wild-type mice were immunized s.c. with 20 µg HBcAg p33-VLPs or wild-type HBcAg as negative control, and draining lymph nodes were removed 16 h after priming. DC, B, and T cells were isolated by FACS cell sorting and cocultured with specific CD8+ T cells to perform a classical [3H]thymidine incorporation assay (Fig. 2). As expected, only DCs, but not B and T cells, could take up HBcAg p33-VLPs and cross-present the p33 epitope to the transgenic T cells and induce their proliferation. This underscores the suitability of VLPs for the specific targeting of Ags and CpG oligonucleotides to APCs.
|
p33-VLPs packaged with CpGs induce strong and protective CTL responsesThe immunogenicity of p33-VLPs loaded with CpGs was tested next. C57BL/6 mice were immunized s.c. with 100 µg HBcAg p33-VLPs mixed together with 20 nmol phosphothioester-stabilized ODN1668pt or packaged with ODN1668pt. Frequencies of specific CD8+ T cells were assessed 8 days later in the blood using p33-loaded MHC tetramers and were observed to be as follows: HBcAg p33-VLP alone, 0.3 ± 0.1%; HBcAg p33-VLP mixed with ODN1668pt, 2.1 ± 0.9%; HBcAg p33-VLP with ODN1668pt packaged, 4.3 ± 1.1%, whereas untreated mice had a median frequency of 0.2% (Fig. 3A). The immunogenicity of VLPs packaged with CpGs was underscored in a second experiment, in which the frequencies of specific T cells induced by live recombinant vaccinia virus expressing the p33-containing LCMV glycoprotein (Vacc-G2) (1.1 ± 0.3%) were directly compared with those induced by HBcAg p33-VLPs packaged with ODN1668pt (5.4 ± 1.4%) (Fig. 3B).
|
|
30% at an E:T ratio of 90 (Fig. 5C). The corresponding killing obtained by the mixed CpGs was only in the range of 15% (Fig. 5B). These results confirm values obtained by p33 tetramer staining of blood lymphocytes, in which a 2-fold increased frequency of p33-specific CD8+ T cells was observed.
|
p33-VLPs and used these for immunization (90 µg, s.c.). CTL responses were assessed by determining numbers of p33 tetramer-positive T cells and protection against Vacc-G2 infection (Figs. 3C and 4C). For both CpG sequences, significantly improved immune responses were obtained when the oligonucleotides were packaged inside the Q capsids. In fact, mixed CpGs induced specific CD8+ T cell frequencies lower than 3%, whereas median numbers for packaged ODNs surpassed 13% (Fig. 3C). Correspondingly, complete viral protection was observed only for Q p33-VLPs packaged with ODNG6po or ODNG3po (Fig. 4C). In conclusion, these results strengthen the hypothesis that selected packaged CpG sequences with normal phosphodiester bonds can generate strong and protective immunity. As expected, mice immunized s.c. with 100 µg HBcAg p33-VLPs either packaged or mixed with a DNA oligonucleotide lacking CpG motifs (ODNLiang2pt) were not significantly protected from viral replication upon challenge infection with Vacc-G2 (data not shown). This indicates that the immune-stimulating activity of DNA oligonucleotides depends on the presence of CpG motifs into the sequence.
Packaging CpGs into HBcAg p33-VLPs results in better immune responses than packaging CpGs in liposomes
To compare the immunogenicity of CpGs packaged into p33-VLPs or liposomes (31, 41), groups of mice were vaccinated s.c. with 100 µg HBcAg p33-VLPs packaged with 0.6 nmol ODN1668pt or with small unilamellar liposomes (mean diameter of 120 ± 30 nm) packaged with 100 µg p33 peptide alone or together with 10 nmol ODN1668pt. Two additional groups of mice were primed with liposomes packaged with 5 µg p33 peptide together with 10 or 0.5 nmol ODN1668pt. Note that 5 µg of p33 epitope and 0.6 nmol CpGs are delivered per HBcAg p33-VLP injection; therefore, a direct comparison between VLPs and liposomes (with the same amounts of Ag and adjuvant) corresponds to a liposome preparation containing 5 µg p33 and 0.5 nmol CpGs. The induced immune responses were assessed next by measuring frequencies of p33-specific T cells and protection against infection with Vacc-G2 (4 x 106 PFU, i.p.) (Figs. 3D and 4D). Packaged HBcAg p33-VLPs induced 6.8 ± 1.1% specific CD8+ T cells and protected mice most efficiently against infection with recombinant vaccinia virus, whereas liposomes packaged with p33 peptide and 10 nmol ODN1668pt generated 3.1 ± 1.2% and 2.9 ± 0.4% of specific CD8+ T cells, for the high and low p33 doses, respectively. The viral protection was intermediate, but still significant when compared with untreated controls. However, the mice treated with liposomes containing 10 nmol CpGs suffered from splenomegaly as side effect due to the high dose of CpGs used (data not shown; see also below). Liposomes packaged with 5 µg p33 together with 0.5 nmol ODN1668pt were by contrast not immunogenic. These data indicate that VLPs are better Ag and adjuvant carriers for the generation of specific T cell responses than liposomes.
A single vaccination with CpG-loaded HBcAg p33-VLPs can cure mice with established fibrosarcoma tumors
To test whether vaccination with packaged CpG may be able to eradicate established tumors, solid fibrosarcoma tumors were transplanted into C57BL/6 mice that were therapeutically vaccinated s.c. with 100 µg HBcAg p33-VLPs packaged with ODN1668pt once the tumors had reached a size of >0.64 cm2, reflecting a large tumor burden. In a first experiment, in six of eight mice, established tumors were completely eradicated and mice remained tumor free for at least 3 mo until the experiment was stopped (Fig. 6A). The other two treated mice controlled the tumor initially, as indicated by a reduction in tumor size early after vaccination. However, tumors started to grow again at a later time point. RT-PCR analysis of isolated tumor tissue demonstrated absence of LCMV-GP expression (data not shown), suggesting that the tumor had escaped CTL-mediated immunosurveillance by loss of LCMV-GP expression or that the cell line, even after cultivation in selection medium was not completely monoclonal (42). In contrast, all five untreated control mice failed to eliminate the tumor. In a second experiment, 7 of 10 mice treated with HBcAg p33-VLPs packaged with ODN1668pt were able to eliminate the tumors (Fig. 6B). Again, individual mice (3 of 10) after initially responding to the therapy were not able to control tumor growth in the long-term. RT-PCR analysis of tumor tissue confirmed the absence or loss of LCMV-GP expression by tumor cells in 2 of 3 mice (data not shown). In both experiments, Student’s t tests confirmed the significance of the data (p < 0.05 when comparing treated vs untreated mice). Moreover, HBcAg p33-VLPs given alone or wild-type VLPs (not containing the p33 epitope) packaged with ODN1668pt failed to noticeably inhibit tumor progression (4 of 5 and 3 of 4 mice did not control the tumor, respectively; p > 0.05 by comparing treated vs untreated mice). Note that Kawarada et al. (43) extensively investigated the efficiency of free CpGs alone for the treatment of various tumors and could show that only repeated peritumoral CpG injections (ODN1668pt) inhibited tumor growth, whereas systemic CpG application had only limited effects.
|
Induction of splenomegaly is a major side effect of CpGs with DNase-resistant phosphorothioate backbones in animal models and especially in rodents. We therefore analyzed spleen weights 12 days (Fig. 7) and 6 days (data not shown) after immunization. Although mice vaccinated s.c. with 100 µg HBcAg p33-VLPs containing packaged ODN1668pt exhibited normal spleen weights, cellularity (Fig. 7, A and B), and histology (Fig. 7, C–F), spleens from mice immunized s.c. with 100 µg HBcAg p33-VLPs mixed with ODN1668pt (20 nmol) exhibited 4-fold increased spleen sizes, and histological analysis indicated that white pulp (dark violet-colored regions) and red pulp (regions appearing red) had largely dissolved. Thus, packaging phosphothioester-stabilized CpGs into VLPs preserved their adjuvant properties, but significantly reduced their systemic toxicity.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
, the CpGs are delivered in a targeted fashion into the optimal APCs. As a consequence, strong CTL responses may be induced in mice in the absence of systemic side effects.
Although CpGs are powerful immune activators, they induce serious side effects such as systemic immune activation and splenomegaly. To minimize the toxic effects of CpGs and deliver them in a more specific way, in this study we established a simple and effective method for packaging short CpG-containing DNA oligonucleotides into HBcAg and Q VLPs. These VLPs have in fact two important characteristics in common, which allow for the packaging of the immunostimulatory DNA: 1) the capsids possess VLP-internal arginine repeats able to bind nucleic acids, and 2) the VLPs exhibit pores of 2 nm in diameter that permit the diffusion of small enzymes such as RNase A and oligonucleotides into the particles (36, 37, 38). Although CpG toxicity and other side effects in humans may be less severe than in rodents, no definitive toxicological data are available yet. Our results indicate that packaging CpGs into VLPs allows reduction of side effects in three different ways: 1) small doses of CpGs are effective at enhancing CTL responses; 2) because professional APCs are the primary cell types known to efficiently take up particles, DCs and M will probably be the major cell populations exposed to the CpGs; and 3) unmodified DNA oligonucleotides may be used, which have a more favorable toxicity profile than the chemically stabilized CpGs.
This study shows that packaging CpGs into VLPs could not only reduce their side effects, but also increased their immune-stimulating effects. In particular, HBcAg p33-VLPs packaged with ODN1668pt were at least 2-fold more immunogenic than p33-VLPs mixed with CpGs, as measured by tetramer-staining and in ex vivo 51Cr release experiments. The results were even more pronounced when Q p33-VLPs were packaged or mixed with unmodified DNA (ODNG3po and ODNG6po). In fact, whereas free CpG coadministered with p33-VLPs generated barely detectable CTL frequencies and did not protect mice from recombinant vaccinia virus challenge, p33-VLPs packaged with CpGs induced very high frequencies of p33-specific T cells (above 10%) and fully protected mice from Vacc-G2 virus replication.
The potency of CpG-loaded VLPs for induction of CTLs was directly compared with a live vaccine, namely recombinant vaccinia virus expressing the LCMV-GP. Surprisingly, the VLPs were much more potent than the recombinant vaccinia virus, perhaps because vaccinia virus simultaneously triggers CTL responses against many epitopes, while it is unlikely that the small VLP monomers (20 kDa) harbor many CTL epitopes. Liposomes are also known to be an effective Ag and adjuvant delivery system for the induction of CTL responses (31, 41, 44). This prompted us to compare side by side the efficiency of p33-VLPs packaged with CpGs and liposomes encapsulated with p33 peptide and CpGs. Confirming previous studies (31, 41, 44), liposomes significantly enhanced the immunogenicity of peptides. Mice immunized with liposomes containing 100 µg p33 with 10 nmol CpGs generated 2–4% of p33-specific T cells and were partly protected from Vacc-G2. Nevertheless, when the amounts of Ag and adjuvant present in the liposomes were adjusted to doses typically packaged into p33-VLPs, liposomes were much less effective than VLPs. It may be possible that the size of the liposomes used (mean diameter of 120 ± 30 nm) was less suitable for efficient uptake by APCs compared with p33-VLPs. Alternatively, protein structures may be more easily taken up by DCs than lipid particulates. In addition, it cannot be excluded that liposomes may fuse not only with cellular membranes of professional APCs, but also of normal tissue cells, and therefore deliver the Ag and the adjuvant in a less specific way.
In conclusion, VLPs loaded with CpGs are able to induce potent T cell responses, reaching levels usually obtained only with live vaccines. In fact, VLPs together with CpGs exhibit the immunologically relevant feature of live viruses, which is efficient Ag presentation by activated professional APCs. VLPs in fact exhibit the proper particle size for phagocytosis, facilitating cross-presentation by professional APCs. At the same time, these APCs are activated by the CpGs liberated within the endosome. This leads to the presentation of the relevant Ags by activated APCs, allowing the induction of optimal T cell responses.
These properties may facilitate the development of human T cell vaccines. In fact, induction of strong CTL responses in humans is still a major problem for vaccination against tumors or chronic viral infections using conventional vaccination strategies. CpG packaged into epitope-carrying VLPs may be ideal candidates for generating therapeutic antiviral or tumor vaccines that have a tolerable side-effect spectrum. Because we packaged CpG into particles formed by the HBcAg, these VLPs may themselves be a promising candidate vaccine for treatment of chronic hepatitis B infection, afflicting globally >350 million people (www.who.int/inf-fs/en/fact204.html).
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Abbreviations used in this paper: CpG, nonmethylated CG motif; DC, dendritic cell; HBcAg, hepatitis B core Ag; LCMV, lymphocytic choriomeningitis virus; LCMV-GP, LCMV glycoprotein; M, macrophage; ODN, oligodeoxynucleotide; po, phosphodiester; pt, phosphorothioate; Vacc-G2, recombinant vaccinia virus expressing glycoprotein of LCMV; VLP, virus-like particle; VLPDEL, VLP composed of HBcAg monomers in which C-terminal region rich in arginine repeats is deleted.
Received for publication July 14, 2003. Accepted for publication November 17, 2003.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J. Immunol. 156:558.[Abstract]
coat protein as a carrier for foreign epitopes. Intervirology 39:9.[Medline]
virus-like particles: from icosahedrons to rods. FEBS Lett. 482:261.[Medline]
This article has been cited by other articles:
|
|
 |
|
  B. Chackerian, M. R. Durfee, and J. T. Schiller Virus-Like Display of a Neo-Self Antigen Reverses B Cell Anergy in a B Cell Receptor Transgenic Mouse Model J. Immunol., May 1, 2008; 180(9): 5816 - 5825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Anderson, G. J. Cianciolo, M. N. Kennedy, and S. V. Pizzo {alpha}2-Macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism J. Leukoc. Biol., February 1, 2008; 83(2): 381 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Agnellini, M. Wiesel, K. Schwarz, P. Wolint, M. F. Bachmann, and A. Oxenius Kinetic and Mechanistic Requirements for Helping CD8 T Cells J. Immunol., February 1, 2008; 180(3): 1517 - 1525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lacasse, J. Denis, R. Lapointe, D. Leclerc, and A. Lamarre Novel Plant Virus-Based Vaccine Induces Protective Cytotoxic T-Lymphocyte-Mediated Antiviral Immunity through Dendritic Cell Maturation J. Virol., January 15, 2008; 82(2): 785 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jegerlehner, P. Maurer, J. Bessa, H. J. Hinton, M. Kopf, and M. F. Bachmann TLR9 Signaling in B Cells Determines Class Switch Recombination to IgG2a J. Immunol., February 15, 2007; 178(4): 2415 - 2420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. S. Liu, J. Dyer, G. R. Leggatt, G. J. P. Fernando, J. Zhong, R. Thomas, and I. H. Frazer Overcoming Original Antigenic Sin to Generate New CD8 T Cell IFN-{gamma} Responses in an Antigen-Experienced Host. J. Immunol., September 1, 2006; 177(5): 2873 - 2879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Pawar, P. S. Patole, M. Wornle, and H.-J. Anders Microbial nucleic acids pay a Toll in kidney disease Am J Physiol Renal Physiol, September 1, 2006; 291(3): F509 - F516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cooper and Y. Shaul Clathrin-mediated Endocytosis and Lysosomal Cleavage of Hepatitis B Virus Capsid-like Core Particles J. Biol. Chem., June 16, 2006; 281(24): 16563 - 16569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Bachmann, P. Wolint, K. Schwarz, and A. Oxenius Recall Proliferation Potential of Memory CD8+ T Cells and Antiviral Protection J. Immunol., October 1, 2005; 175(7): 4677 - 4685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Bachmann, P. Wolint, K. Schwarz, P. Jager, and A. Oxenius Functional Properties and Lineage Relationship of CD8+ T Cell Subsets Identified by Expression of IL-7 Receptor {alpha} and CD62L J. Immunol., October 1, 2005; 175(7): 4686 - 4696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ruedl, K. Schwarz, A. Jegerlehner, T. Storni, V. Manolova, and M. F. Bachmann Virus-Like Particles as Carriers for T-Cell Epitopes: Limited Inhibition of T-Cell Priming by Carrier-Specific Antibodies J. Virol., January 15, 2005; 79(2): 717 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Vanlandschoot, F. Van Houtte, B. Serruys, and G. Leroux-Roels The arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfate J. Gen. Virol., January 1, 2005; 86(1): 75 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Bachmann, K. Schwarz, P. Wolint, E. Meijerink, S. Martin, V. Manolova, and A. Oxenius Cutting Edge: Distinct Roles for T Help and CD40/CD40 Ligand in Regulating Differentiation of Proliferation-Competent Memory CD8+ T Cells J. Immunol., August 15, 2004; 173(4): 2217 - 2221. [Abstract] [Full Text] [PDF]
|
|
|
). Value of p < 0.05 (two-tailed Student’s t test) were observed by comparing treated vs untreated mice. Mice in which tumors were reaching sizes of >3–4 cm2 were sacrificed for regulatory reasons. Note that no LCMV-GP expression could be detected by RT-PCR in the tumors of the two vaccinated mice that failed to control the tumor in experiment A and in two of three that failed therapy in experiment B. A and B, Represent two independent experiments.